Marinomed Biotech AG Explores Strategic Opportunities for Carragelose Portfolio

• Marinomed Biotech AG is evaluating strategic options for its Carragelose business and has hired an external advisor.
• The change in regulatory legislation for medical devices creates a favorable market environment for Carragelose products.
• Marinomed will focus on its core competencies of research and development and generation of intellectual property (IP).
• Carragelose products fulfill all necessary prerequisites for the new EU medical device regulation (MDR) and have extensive clinical data supporting their efficacy.
• Marinomed is considering strategic partnerships or transferring the Carragelose portfolio to a partner to maximize its value.
• Marinomed aims to become profitable in 2024 and is also negotiating the restructuring of debt with the EIB.

The next important date, Quarterly report, at Marinomed Biotech is on 12.02.2024.

Marinomed Biotech

0,00 %

-0,35 %

-11,91 %

-37,00 %

-67,17 %

-88,67 %

-82,55 %

-81,75 %

-81,29 %

ISIN:ATMARINOMED6WKN:A2N9MM

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max